Re-Assessing PK/PD Issues for Oral Protein and Peptide Delivery
| Autor: | Mahmood Tahir, Randall J. Mrsny |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pharmaceutical drug
medicine.medical_treatment Pharmaceutical Science Peptide Pharmacology 03 medical and health sciences 0302 clinical medicine Pharmacy and materia medica Pharmacokinetics Oral administration hepatic portal vasculature medicine PK/PD models 030304 developmental biology chemistry.chemical_classification 0303 health sciences business.industry pharmacokinetics and pharmacodynamics RS1-441 Biopharmaceutical chemistry 030220 oncology & carcinogenesis Pharmacodynamics oral biopharmaceutical delivery Commentary business |
| Zdroj: | Pharmaceutics, Vol 13, Iss 1006, p 1006 (2021) Pharmaceutics |
| ISSN: | 1999-4923 |
| Popis: | Due to a lack of safe and effective oral delivery strategies for most protein and peptide therapeutics, pharmaceutical drug developers have focused on parenteral routes to administer these agents. Recent advances in delivery technologies have now shown clinical validation for a few of these biopharmaceuticals following oral administration. While these initial opportunities have provided more than just a glimmer of hope within the industry, there are important aspects of oral biopharmaceutical delivery that do not completely align with pharmacokinetic (PK) parameters and pharmacodynamics (PD) outcomes that have been learned from parenteral administrations. This commentary examines some of these issues with the goal of presenting a rationale for re-assessing methods, models, and success criteria to better measure oral protein or peptide delivery outcomes related to PK/PD events. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|